The DOI matches its Crossref record; 190 of the 194 references it cites were found in a registry or an index; 91 of the 133 sources its claims cite were checked for support.
Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories
Open accessAbstract
In a subset of patients, chronic exposure to stress is an etiological risk factor for neuroinflammation and depression. Neuroinflammation affects up to 27% of patients with MDD and is associated with a more severe, chronic, and treatment-resistant trajectory. Inflammation is not unique to depression and has transdiagnostic effects suggesting a shared etiological risk factor underlying psychopathologies and metabolic disorders. Research supports an association but not necessarily a causation with depression. Putative mechanisms link chronic stress to dysregulation of the HPA axis and immune cell glucocorticoid resistance resulting in hyperactivation of the peripheral immune system. The chronic extracellular release of DAMPs and immune cell DAMP-PRR signaling creates a feed forward loop that accelerates peripheral and central inflammation. Higher plasma levels of inflammatory cytokines, most consistently interleukin IL-1β, IL-6, and TNF-α, are correlated with greater depressive symptomatology. Cytokines sensitize the HPA axis, disrupt the negative feedback loop, and further propagate inflammatory reactions. Peripheral inflammation exacerbates central inflammation (neuroinflammation) through several mechanisms including disruption of the blood-brain barrier, immune cellular trafficking, and activation of glial cells. Activated glial cells release cytokines, chemokines, and reactive oxygen and nitrogen species into the extra-synaptic space dysregulating neurotransmitter systems, imbalancing the excitatory to inhibitory ratio, and disrupting neural circuitry plasticity and adaptation. In particular, microglial activation and toxicity plays a central role in the pathophysiology of neuroinflammation. Magnetic resonance imaging (MRI) studies most consistently show reduced hippocampal volumes. Neural circuitry dysfunction such as hypoactivation between the ventral striatum and the ventromedial prefrontal cortex underlies the melancholic phenotype of depression. Chronic administration of monoamine-based antidepressants counters the inflammatory response, but with a delayed therapeutic onset. Therapeutics targeting cell mediated immunity, generalized and specific inflammatory signaling pathways, and nitro-oxidative stress have enormous potential to advance the treatment landscape. Future clinical trials will need to include immune system perturbations as biomarker outcome measures to facilitate novel antidepressant development. In this overview, we explore the inflammatory correlates of depression and elucidate pathomechanisms to facilitate the development of novel biomarkers and therapeutics.
Overview
CoChat Summary
TL;DR
This narrative review links chronic stress to HPA-axis dysregulation, immune-cell glucocorticoid resistance, DAMP-PRR signaling, peripheral and central inflammation, and depression. It argues that neuroinflammation defines a severe, treatment-resistant depressive subtype and reviews emerging anti-inflammatory and targeted immunomodulatory treatments.
Key findings
- Neuroinflammation affects up to 27% of patients with MDD and is associated with a more severe, chronic, treatment-resistant trajectory; peripheral CRP >3 mg/L is commonly used to subtype inflammation and correlates with CSF CRP.
- Chronic stress is proposed to drive HPA-axis dysregulation and glucocorticoid resistance, with elevated IL-1β, IL-6, and TNF-α; in preclinical work, peripheral IL-6 was 27 times higher in susceptible versus resilient mice after repeated social defeat stress, and anti-IL-6 before stress prevented social avoidance.
- Central effects include BBB disruption, glial activation, and neurotransmitter/network dysfunction; a meta-analysis estimated an 18% increase in TSPO availability in depressed patients, minocycline improved depression with effect sizes as high as 0.71, and MRI most consistently shows reduced hippocampal volumes.
- Anti-inflammatory augmentation may help: adjunctive anti-inflammatory treatment was reported as 52% more effective than placebo, celecoxib plus sertraline made response 7 times more likely, anti-cytokine treatment had a moderate effect size (Cohen’s d = 0.40), and infliximab reduced HAM-D at week 12 in patients with baseline CRP >5 mg/L.
Methods
- Narrative overview of pathophysiological mechanisms and emerging anti-inflammatories; no primary data collection or systematic review protocol is described.
- Synthesizes preclinical animal models, clinical observational studies, postmortem and neuroimaging findings, randomized trials, and meta-analyses.
- Main analysis is qualitative synthesis, with tables summarizing inflammatory mediators, proposed roles, and emerging therapeutic targets.
Limitations
- The paper states that evidence linking chronic stress, inflammation, and depression is largely observational and supports association but not necessarily causation.
- It states that anti-inflammatory data interpretation is limited by small numbers of studies, moderate to large heterogeneity, variations in diagnostic and treatment planning, and inclusion of patients without evidence of inflammation; targeted therapies are mostly limited to animal models or patients with autoimmune/rheumatological conditions.
- Evident from the text: as a narrative review, it does not describe a systematic search strategy, formal risk-of-bias assessment, or quantitative pooling of the reviewed literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
87 Valid · 8 Not valid · 42 Not checked · 27 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, persistent stress overstimulates the HPA axis causing an excess release of cortisol.”
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > Hypothalamic–pituitary–adrenal axis
What the sources say
- Supportedcites [16] Mikulska, 2021, HPA Axis in the Pathomechanism of depression and schizophrenia: new therapeutic strategies based on its participation, Brain Sci source
Section 7 states that chronic stress is associated with excessive activation of the HPA axis and that activation culminates in cortisol secretion. Section 3 also links chronic stress to elevated cortisol levels through HPA-axis dysregulation. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinical studies have corroborated that depressed patients have higher serum levels of IL-1β compared to non-depressed patients.”
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > Pattern-recognition receptors > NLRP3
What the sources say
- Partly supportedcites [51] Ferentinos, 2021, Interleukin-1 Beta in peripheral blood mononuclear cell lysates as a longitudinal biomarker of response to antidepressants: a pilot study, Front Psych sourceExperimental — accuracy not yet measured
The Discussion reports that a meta-analysis found higher circulating IL-1β in patients with major depressive disorder, but only among high-quality studies; it also says other meta-analyses found no significant difference. This study measured plasma rather than serum, and its Results found no significant patient–control difference in plasma IL-1β. It therefore does not support the unqualified claim about higher serum levels. (LLM, conf=0.86)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A meta-analysis reported higher levels of serum pro-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-12, TNF-α) and reduced anti-inflammatory cytokines (IL-4, IL-10, transforming growth factor [TGF]-β1) in depressed compared to non-depressed patients (62).”
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > Cytokines
What the sources say
- Partly supportedcites [62] Osimo, 2020, Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls, Brain Behav Immun sourceExperimental — accuracy not yet measured
The Results (Mean differences) report higher IL-1β, IL-2, IL-6, IL-12 and TNF-α, and lower IL-4, in patients with depression than in controls. But they report higher—not lower—IL-10 and no significant difference in TGF-β, so the claimed reductions in those two markers are not supported. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Approximately 30% of patients with hepatitis C develop major depression within the first 3 months of receiving IFN-α (63).”
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > Cytokines
What the sources say
- Partly supportedcites [63] Chiu, 2017, Recurrence of depressive disorders after interferon-induced depression, Transl Psychiatry sourceExperimental — accuracy not yet measured
The Introduction says that up to 30% of IFN-α-treated patients with hepatitis C develop a major depressive episode within the first three months. The citing sentence preserves the population, condition and timing, but “approximately 30%” presents the source’s upper bound as an approximate rate. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The NLR3P inflammasome mediates proteolytic cleave of pro-caspase-1 leading to activation of caspase-1, which cleaves pro-interleukin 1β and 18 into their active cytokine forms (47).”
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > Pattern-recognition receptors > NLRP3
What the sources say
- Supportedcites [47] Guo, 2015, Inflammasomes: mechanism of action, role in disease, and therapeutics, Nat Med source
The NLRP3 inflammasome section says that pro-caspase-1 undergoes auto-proteolytic maturation into active caspase-1. The Introduction says active caspase-1 cleaves IL-1-family precursors into bioactive IL-1β and IL-18. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
99 more claims · 56 with their cited sources checked
Create a free account to see all 164 claims and every source verdict.
- It may state two separate claims as one. 50
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > Cytokines
“Yamano and colleagues reversed INF-α induced stress susceptibility in mice with a corticotropin-releasing hormone receptor antagonist in a dose dependent fashion, suggesting that overactivity of the HPA axis mediates the cytokine depression response (64).”
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > References
“64. Yamano M Tohyama M. Distribution of corticotropin-releasing factor and calcitonin gene-related peptide in the developing mouse cerebellum.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > Damage-associated molecular patterns > S100B
“A 12-week randomized, placebo-controlled study found that pioglitazone, an insulin-sensitizing drug, improved glucose control and reduced chronic depression in patients with type II diabetes (28).”
§ Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories > References
“28. Li X Wilder-Smith CH Kan ME Lu J Cao Y Wong RK. Combat-training stress in soldiers increases S100B, a marker of increased blood-brain-barrier permeability, and induces immune activation.”
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931 · cited 1×
“Activated macrophages and microglia release ROS that disrupt cell membranes, cellular DNA, and protein synthesis (101).”
BackgroundNitric oxide synthases: regulation and function
Forstermann, U., & Sessa, W. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr304 · Cited by 4,409 · cited 1×
“Nitrosative stress occurs when there is an abnormal increase in the level of nitric oxide (NO) produced by the inducible isoenzymes of NO synthase: neuronal, inducible, and endothelial (113).”
BackgroundThe NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 2×
“NLRP3 inflammasome (48) NLRP3 mediates proteolytic cleave of procaspase-1 leading to activation of caspase 1, IL-1β”
BackgroundDifferentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · cited 1×
“Treg cells suppress the immune response whereas Th cells trigger immunological responses (65).”
BackgroundInflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340 · cited 2×
“Several PRRs, toll-like receptor-4 (TLR-4) and NLR family pyrin domain containing 3 (NLRP3), have been implicated in depression (47).”
BackgroundMechanisms, regulation and functions of the unfolded protein response
Hetz, C., Zhang, K., & Kaufman, R. J. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0250-z · Cited by 2,666 · cited 1×
“The function of the endoplasmic reticulum (ER) is to properly fold proteins and traffic them to various organelles and the cell membrane (37).”
BackgroundThe blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661 · cited 1×
“BMECs are connected to each other by tight junctions, GAP junctions, and adherens junctions (82).”
BackgroundThe Bidirectional Relationship of Depression and Inflammation: Double Trouble
Beurel, E., Toups, M., & Nemeroff, C. B. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.002 · Cited by 2,136 · cited 1×
“Modulation of NF-κB signaling is currently being investigated as an approach to treat major depression (80).”
BackgroundMarine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Calder, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.010 · Cited by 1,717 · cited 1×
“EPA and DHA ameliorate inflammation by inhibiting leukocyte chemotaxis, adhesion molecule expression, and the production of inflammatory cytokines and prostaglandins (164).”
Background
Cited by
PI3K/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression
Guo, N., Wang, X., Xu, M., Bai, J., Yu, H., & Zhang, L. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107300 · Cited by 218
Effects of chronic stress on cognitive function – From neurobiology to intervention
Girotti, M., Bulin, S. E., & Carreno, F. R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100670 · Cited by 206
“We refer the interested reader to comprehensive reviews on the subject (Carrier et al., 2021; Godoy et al., 2018; Gray et al., 2017; Hassamal 2023; McEwen and Akil 2020).”
MethodSharma, S., Chawla, S., Kumar, P., Ahmad, R., & Verma, P. K. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149123 · Cited by 107
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 103
“The resulting DA and NE deficiency is associated with treatment‑resistant somatic symptoms subsequent desensitization of the HPA axis [139].”
BackgroundDepression and coronary heart disease: mechanisms, interventions, and treatments
Xu, L., Zhai, X., Shi, D., & Zhang, Y. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1328048 · Cited by 97
Metadata
- Authors
- Hassamal, S.
- Affiliations
- California University of Science and Medicine (US)
- Corresponding author
- Hassamal, Sameer
- ORCID
- Hassamal, Sameer
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-05-11
- Volume
- 14
- Pages
- 1130989-1130989
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC10213648
- OpenAlex
- W4376279472
- Semantic Scholar
- 38bc0fd145aaecf15f84b2c481c52f74bd9d9788
- Cited by
- 578
- References
- 194
- Citations by year
- 2026: 223 · 2025: 239 · 2024: 103 · 2023: 13
- FWCI
- 11.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- chronic stress, neuroinflammation, depression, major depressive disorder, HPA axis dysregulation, glucocorticoid resistance, peripheral inflammation, cytokines, blood-brain barrier, microglial activation, glial cells, hippocampal volume, ventral striatum, ventromedial prefrontal cortex, nitro-oxidative stress, inflammatory markers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. https://app.cochat.ai/papers/10.3389/fpsyt.2023.1130989
- The paper
- Hassamal, S. (2023). Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1130989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.